Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of DC-TAB in Healthy Volunteers
NCT02442557Phase 1Completed
- Start
- Dec 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SER-101 in multiple sclerosis (MS) (9 arms). Primary endpoint: Safety (adverse events) at 28 days. Started Dec 2009; status: completed.
02
Drugs
SER-101
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02442557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442557.